经过23.7个月的中位随访,所有患者的2年总生存(overall survival,OS)率和无进展生存(progression-free survival,PFS)率分别为85.3%和53.7%。
基于1个网页-相关网页
Progression-Free Survival 无进展生存期 ; 无进展生存时间
progression free interval 进展间期 ; 中位无进展间期 ; 无进展间期
progression-free survival rate 无病存活率
progression free survival time 无进展生存期
median progression free survival 和中位无进展生存期
The median progression-free survival period with the drug combination was 11.8 months, twice as long as the 5.9 months achieved with paclitaxel alone.
药物联用的中值无进展存活期为11.8个月,是用单独紫杉醇获得的5.9个月的两倍。
Thus, surrogate endpoints like response rate and progression-free survival are commonly accepted, although all parties involved realize the risk involved.
因此,替代终点如反应率和无进展生存率被普遍接受,尽管各方意识到风险所在。
FDA gave its blessing based on a trial showing it offered breast cancer patients an extra 5.5 months of "progression-free survival," time when their tumors weren't growing.
FDA是基于阿瓦斯丁可以让患者的肿瘤在5个半月内都不增长的研究,批准了阿瓦斯丁的使用许可。
应用推荐